Is Aspen betting on the right HIV prevention product?

Aspen Pharmacare has announced that it will not be manufacturing the lenacapavir HIV prevention injection, and that it will instead focus on producing alimatravir, an experimental HIV prevention pill. Catherine Tomlinson explores the reasoning behind Aspen’s decision and assesses what it all means for local pharmaceutical production.

Read More

In The Spotlight | A fungal infection that targets the brain claims many lives in SA, stopping it won’t be easy

One of the top killers of people living with HIV in South Africa is a fungal infection caused by spores found all around us. In this Spotlight special briefing, Elri Voigt unpacks what we know about this dangerous disease called cryptococcal meningitis, why it remains so deadly, and what we can do about it.

Read More

“This one was brought by God himself” – the doctor helping people see again in rural KZN

As a young doctor working in rural KwaZulu-Natal, Hennie Hamilton lived with a Zulu family for four years, an experience which, he says, changed him forever. Twenty-three years later, he’s still working in the area as medical manager at Mosvold Hospital and doing cataract surgery on patients from five rural hospitals.

Read More

This specialist forensic nurse in Germiston helped put a serial rapist behind bars

In a country like South Africa which grapples with a high prevalence of gender-based violence, forensic nursing unfortunately remains a largely overlooked specialisation, with little incentive for remuneration. One nurse tells Elna Schütz every flicker of hope a patient carries home is a reminder of why she chose this path.

Read More

SA is one step closer to a new TB vaccine, but there is a lot of work ahead

In March 2024, a pivotal clinical trial was launched to evaluate what might well become the first new tuberculosis vaccine on the market in more than a century. As anticipation mounts for the trial to deliver results, Russell Rensburg argues that we need to start preparing for a rollout of the jab, but that we should think of preparation more widely than just the technicalities of regulatory approval and drug supply.

Read More